Alzheimer's treatment
In an unexpected
reversal, pharmaceutical giant Biogen said it will pursue US Food and Drug
Administration approval for aducanumab, an experimental treatment for early
Alzheimer's disease, Biogen and its Japanese partner Eisai announced on
Tuesday.
Phase 3 clinical
studies of aducanumab were discontinued in March. The trials were halted
because results of a futility analysis found they were unlikely to meet their
primary goals at completion.
On Tuesday, Biogen
announced that a new analysis, which included more patients, showed a
significant reduction in clinical decline in one trial. Results for some
patients in another study support those findings, as well.
The data showed that
patients who received aducanumab experienced significant benefits on measures
of cognition and function, including memory, orientation and language,
according to Biogen... https://edition.cnn.com/2019/10/22/health/biogen-alzheimers-drug-fda/index.html